Cetuximab biosimilar - Shanghai Zhangjiang Biotechnology

Drug Profile

Cetuximab biosimilar - Shanghai Zhangjiang Biotechnology

Alternative Names: CMAB-009

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Zhangjiang Biotechnology
  • Developer Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Colorectal cancer

Most Recent Events

  • 17 May 2017 Efficacy and adverse event data from a phase II/III trial in Colorectal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Dec 2015 Shanghai Zhangjiang Biotechnology completes a phase II/III trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (NCT01550055)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top